Company Overview
- CentricsBio Inc. is a biotech venture company established
in 2017 with the goal of developing new global drugs. Having held
the patent for a cancer immunotherapy drug, we develop more
innovative drugs using that. - Our company currently has its head office/research center in Munjeong-dong, Songpa-gu, and is conducting joint research by forming networks with leading domestic and overseas research institutes to expand various pipelines and indications. Based on this potential, CentricsBio Inc. has already succeeded in attracting a large number of investments, and all employees are striving to launch a new blockbuster drug to become a worldwide company.
Company Milestones
2021
- 12The national new medicine development project was selected as a governmental task
(2 billion won) - 10CB301 original patent divisional application
- 09The publication of the contents of a research by the European Cancer Society (ESMO)
- 07CB301 original patent registration
- 05CB302 combination therapy patent application
- 05CB304 biomarker patent application.
- 05The CRO contract for developing a medicine for Alzheimer’s disease
2020
- 11CB303 PCT application
- 10CB301 Patent applications for leading countries
(6 countries including the United States) - 093rd investment promotion
- 09Collaborative research contract with Cha University Bundang Medical Center
- 01CB304 patent application
2019
- 11CB303 patent application
- 10Patent application for new improved CB301
- 072nd investment promotion
- 06CB301 PCT application
- 051st investment promotion
- 04Registered as SME
2018
- 05CB301 patent application
- 03Development of antibody platform technology and establishment of non-clinical test
2017
- 06CentricsBio founded